Idiopathic pulmonary fibrosis (IPF) is a chronic pathological disorder. Here, Creative Biolabs presents you with a novel pulmonary fibrosis-on-a-chip model that is created to model the fibrotic transition of the lung interstitial tissue and the effect of anti-fibrosis drugs on such transitions.
The pulmonary fibrosis-on-a-chip model consists of arrays of membranous 3D microtissue. During the formation, microtissues undergo morphological and structural changes that are guided by poly (dimethyl siloxane) (PDMS) micropillar-defined mechanical boundary conditions. These membranous lung microtissues recapitulate key biomechanical properties of both healthy and fibrotic lung alveolar tissues.
Fig 1. PDMS microdevice is casted in a P35 dish. (Asmani, 2021)
Our Advantages |
|
Applications |
|
Our pulmonary fibrosis-on-a-chip model offers a range of valuable benefits. It accelerates the analysis of anti-fibrotic therapies, enabling faster assessment of their efficacy. Additionally, it aids in uncovering the underlying mechanisms of action for these therapies, contributing to a deeper understanding of lung biology. This model also serves as a personalized medicine tool, allowing for a better understanding and prediction of treatment effects specific to individual patients.
Apart from the pulmonary fibrosis-on-a-chip model, there are also other models that might capture your interest:
Enriching our comprehensive array of disease-on-a-chip models, Creative Biolabs extends its offerings to encompass a range of specialized technical services, tailored to meet the diverse research requirements of our worldwide clients. Feel free to contact us to explore the potential of our extensively customizable models and to obtain a detailed quote.
Reference